In addition, we designed and screened siRNAs targeting the conserved region of TUG1 as RNAi drug candidates, which inhibited tumor growth and progression as well as improved T cell-induced antitumor immune activity both in vitro and in vivo. Here, TUG1 is linked to neoplasm.